Recida Therapeutics

About Us

Recida Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of novel-class antibiotics to address the expanding problem of multi-drug resistant gram-negative bacteria.

Press Releases

Menlo Park, Calif., February 6, 2019 – Frazier Healthcare Partners today announced the launch of Recida Therapeutics, Inc., a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections. 

Pipeline

RC-01, a novel LpxC inhibitor, displays highly potent inhibitory activity against the bacterial LpxC enzyme with an IC50 at subnanomolar levels.